What Is Mounjaro Used For Besides Weight Loss? (October 2026)

01 · The core answer

What Mounjaro is used for besides weight loss

Besides weight management, Mounjaro is licensed in the UK for type 2 diabetes.¹ It is a once-weekly injectable prescription medicine made by Eli Lilly, supplied as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Those are the only licensed uses. You may see articles listing a dozen other benefits. Most of them describe research directions or downstream effects of weight change, not separate approved uses. Our guide to what else tirzepatide is used for goes through that wider picture in more detail.

If you are asking because you have diabetes, a sleep problem or another condition, the decision is about suitability, not just the label. A prescriber needs your full history before recommending anything.

02 · Your next step

Is this relevant to you?

It is relevant if you are an adult looking at weight management, or if you already live with type 2 diabetes and want to understand the medicine. Both are within the licence.¹ If your interest is a different condition, speak to your GP or specialist first, because they know your wider health picture.

If weight management is part of your goal, our weight loss clinic explains how treatment works. The Mounjaro pen is where you start a free consultation. A GPhC-registered prescriber reviews each consultation, and unsuitable orders are refunded automatically.

03 · How it works

How tirzepatide works for blood sugar and weight

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹

That explains why one medicine has two licensed uses. Slower stomach emptying and a better insulin response are relevant to blood sugar. The effect on appetite is relevant to weight. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic).¹ Our explainer on the wider benefits of GLP-1 medicines covers how this drug class is being discussed beyond weight.

On the weight side, the headline trial is SURMOUNT-1. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, and individual results vary. Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

04 · Sleep apnoea and research

Sleep apnoea and other areas being studied

Obstructive sleep apnoea is the best-known area researchers have examined alongside tirzepatide, in a published trial called SURMOUNT-OSA, which studied people with the condition and obesity.¹⁶

What matters for you is the distinction. A published trial is evidence that a question is worth asking. It is not the same as a licence, and it does not mean a prescriber will offer Mounjaro for that reason alone. If you have sleep apnoea, your sleep clinic or GP remains the right person to guide treatment, including any breathing support you already use.

The same applies to heart health, fatty liver, joint pain and other conditions you may see mentioned. Weight change can affect many parts of health, so it is natural to see related effects discussed. Those discussions are not additional licensed uses. Our page on the benefits of Mounjaro besides weight loss separates what the evidence supports from what is still being explored.

A symptom that is not on the UK patient leaflet's side-effect list is not a listed side effect. Talk to your prescriber about anything new, and report suspected side effects through the Yellow Card scheme.¹⁹

05 · Safety and side effects

Side effects, pancreatitis and who should not take it

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.¹³¹ There is no proven way to prevent pancreatitis or gallbladder problems while taking Mounjaro.

Before you start, tell your prescriber if you have ever had pancreatitis, gallstones or gallbladder disease, or severe problems with your digestion. If you develop severe, persistent stomach pain that may spread to the back, with or without being sick, stop using Mounjaro and get medical help straight away. Pain in the upper right of the abdomen, fever or yellowing of the skin or eyes could be a gallbladder problem: get medical help straight away. You can report suspected side effects through the Yellow Card scheme.¹⁹

Mounjaro should not be taken if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive; it must be stopped at least one month before trying to conceive. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems. This is why our consultation asks about your health history, and why unsuitable orders are refunded automatically. Our prescribing team also offers ongoing monthly reviews and side-effect support once you are on treatment.

The honest answer is that it is a prescription-only medicine because it carries real risks as well as real benefits, and that is the reason it needs a proper review. Mounjaro is supplied only after an online consultation reviewed by a GPhC-registered prescriber.¹

06 · Interactions and alcohol

Interactions, contraception and alcohol

Mounjaro can reduce absorption of oral contraceptives because stomach emptying slows.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹

If you take insulin or a sulfonylurea for diabetes, doses may need adjusting because of the risk of low blood sugar.¹³ That is a conversation for your prescriber or diabetes team before you start. It is not a reason to change your medicines yourself.

There is no direct interaction between Mounjaro and alcohol, but drinking on a reduced appetite and emptier stomach can hit harder than usual. If you also take insulin or a sulfonylurea, alcohol increases the risk of low blood sugar. In practice, many people find that a medicine which makes them feel full sooner changes how they feel about large meals, so smaller portions are often more comfortable. Treat that as general good sense rather than a rule, and raise any persistent stomach symptoms at your review.

Always list every medicine, supplement and herbal product you take, including over-the-counter ones. A prescriber cannot check an interaction they have not been told about.

07 · Mounjaro and Ozempic

Mounjaro compared with Ozempic

Mounjaro and Ozempic are different medicines, so neither is simply better for everyone. Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Ozempic contains semaglutide, a single-action GLP-1 medicine.¹

A head-to-head trial in type 2 diabetes, SURPASS-2, compared tirzepatide with semaglutide once weekly.³ Which suits you depends on your diagnosis, other medicines, tolerance and what a prescriber judges appropriate.

If weight is your main goal, note that Ozempic is semaglutide licensed for type 2 diabetes. It is not a UK weight-loss medicine, and the licensed weight-management options are Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg). Our page on whether Mounjaro is used for weight loss explains how the licence applies to each.

08 · NHS access

Getting Mounjaro on the NHS

Mounjaro is available on the NHS, but access is being phased in over several years.⁴ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition. The NHS primary-care rollout began in June 2025 with the highest-need groups first.⁴⁶

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting. If you want to understand the NHS route first, read our guide to help with weight loss on the NHS, and speak to your GP.

09 · Avoiding false claims

Dramatic claims, supplements and counterfeit risk

You may see dramatic weight-loss claims for pills or supplements. Treat those with caution. Low-cost supplements are available cheaply without assessment, have no clinical oversight, and dosing is not standardised. They are not the same thing as a licensed medicine.

Mounjaro itself should only come from a regulated pharmacy after a consultation and prescription. The MHRA publishes counterfeit medicine alerts, and anyone offering to supply it without a consultation or prescription should be avoided.⁷ You can check our registration on the GPhC register under number 9012878. We supply genuine KwikPens through official LillyDirect supply, direct from Eli Lilly's UK distribution.

Honest expectations matter too. Trial averages do not predict your own result, and treatment works alongside a reduced-calorie diet and increased physical activity.²

10 · Stopping and storage

Stopping treatment and storing the pen

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system.¹ There is no way to speed this up, and nothing needs doing while it clears. Mounjaro manages weight; it does not cure the biology behind it. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.

Keep unopened pens in the fridge until first use, within 2–8°C, and they keep until the printed expiry date.¹³ Once in use, a KwikPen can stay out of the fridge for up to 30 days (not above 30°C).¹³ For anything beyond that, follow the patient information leaflet and ask the pharmacy.